VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the 11th Annual Immunization and Vaccine (“IMVACS”) Summit on Wednesday, December 7, 2016 at 11:30 AM ET. The event is being held at the Revere Hotel Boston Common in Boston, MA.
During the presentation, Enveloped Virus-like Particles, Dr. David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will provide an overview of VBI’s eVLP Platform and an update on the company’s cytomegalovirus (“CMV”) vaccine program. Dr. Anderson will also participate in a panel discussion on the future of vaccine technologies.VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely resemble the structure of enveloped viruses. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. VBI's lead eVLP candidate is a preventative CMV vaccine.
CMV can cause serious disease in newborns when a mother is infected during pregnancy. In September 2016, VBI announced that it had completed enrollment and initial dosing of all participants in a Phase I clinical study to evaluate its CMV vaccine candidate. The Phase I study is designed to assess the safety and tolerability of VBI’s CMV vaccine candidate in healthy CMV-negative adults. The study will also measure levels of vaccine-induced CMV neutralizing antibodies that may prevent CMV infection. Preliminary study results are anticipated in the first half of 2017.
The IMVACS Summit brings together a global audience of vaccine researchers and developers with coverage of adjuvants, vaccines, and immunotherapy technologies. For more information, visit: http://www.imvacs.com/.
- Event: 11th Annual Immunization and Vaccine (“IMVACS”) Summit
- Date: Wednesday, December 7, 2016
- Time: 11:30 AM ET
- Location: Revere Hotel Boston Common in Boston, MA
- Event Website: http://www.imvacs.com